Ricardo V Lloyd

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. Lloyd R, Hardin H, Montemayor Garcia C, Rotondo F, Syro L, Horvath E, et al. Stem cells and cancer stem-like cells in endocrine tissues. Endocr Pathol. 2013;24:1-10 pubmed publisher
    ..New discoveries in this field may lead to more effective therapies for highly aggressive and lethal endocrine cancers. ..
  2. Chu Y, Hardin H, Eickhoff J, Lloyd R. In Situ Hybridization Analysis of Long Non-coding RNAs MALAT1 and HOTAIR in Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Pathol. 2019;: pubmed publisher
    ..05). In summary, MALAT1 and HOTAIR are commonly expressed in GEP-NENs. High expression of either lncRNA showed grade-independent associations with clinically less aggressive disease. ..
  3. Hardin H, Helein H, Meyer K, Robertson S, Zhang R, Zhong W, et al. Thyroid cancer stem-like cell exosomes: regulation of EMT via transfer of lncRNAs. Lab Invest. 2018;98:1133-1142 pubmed publisher
    ..Therapies directed towards CSCs, their exosomes and/or the lncRNAs they carry may reduce a tumor's metastatic capacity. ..
  4. Rosenbaum J, Lloyd R. Pancreatic Neuroendocrine Neoplasms. Surg Pathol Clin. 2014;7:559-75 pubmed publisher
    ..This article reviews the current categorization and features of Pan-NENs. ..
  5. Zhang R, Hardin H, Chen J, Guo Z, Lloyd R. Non-Coding RNAs in Thyroid Cancer. Endocr Pathol. 2016;27:12-20 pubmed publisher
    ..In this review, we will discuss the recent progress in our understanding of the relationship between ncRNAs and the development of thyroid cancers and the potential uses of ncRNAs in the diagnosis and prognosis of thyroid tumors. ..
  6. Hardin H, Yu X, Harrison A, Larrain C, Zhang R, Chen J, et al. Generation of Novel Thyroid Cancer Stem-Like Cell Clones: Effects of Resveratrol and Valproic Acid. Am J Pathol. 2016;186:1662-73 pubmed publisher
    ..For the first time, we have two thyroid CSC lines that will be useful tools for the study of thyroid CSC targeted therapies. ..
  7. Guo Z, Lloyd R. Use of monoclonal antibodies to detect specific mutations in formalin-fixed, paraffin-embedded tissue sections. Hum Pathol. 2016;53:168-77 pubmed publisher
    ..This review will discuss the use of selected mainly monoclonal antibodies targeting specific mutated molecules and indicate how the detection of these proteins can be used for chemotherapeutic purposes in targeting mutated genes. ..
  8. Zhang R, Hardin H, Huang W, Buehler D, Lloyd R. Long Non-coding RNA Linc-ROR Is Upregulated in Papillary Thyroid Carcinoma. Endocr Pathol. 2018;29:1-8 pubmed publisher
    ..These results indicate that ROR, PVT1, and HOTAIR have important regulatory roles during the development of PTCs. ..
  9. request reprint
    Chu Y, Lloyd R. Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression. Endocr Pathol. 2016;27:312-324 pubmed
    ..Multiple miRNA deregulations have been discovered in MTC with potential prognostic and therapeutic implications. This review provides an overview of the basic pathology of MTC and an update on recent investigational progress. ..

More Information

Publications17

  1. Zhang R, Hardin H, Huang W, Chen J, Asioli S, Righi A, et al. MALAT1 Long Non-coding RNA Expression in Thyroid Tissues: Analysis by In Situ Hybridization and Real-Time PCR. Endocr Pathol. 2017;28:7-12 pubmed publisher
    ..Our findings support the notion that ATCs may be molecularly distinct from low-grade thyroid malignancies and suggest that MALAT1 may function both as an oncogene and as a tumor suppressor in different types of thyroid tumors. ..
  2. Lloyd R, Buehler D, Khanafshar E. Papillary thyroid carcinoma variants. Head Neck Pathol. 2011;5:51-6 pubmed publisher
  3. Covach A, Patel S, Hardin H, Lloyd R. Phosphorylated Mechanistic Target of Rapamycin (p-mTOR) and Noncoding RNA Expression in Follicular and Hürthle Cell Thyroid Neoplasm. Endocr Pathol. 2017;28:207-212 pubmed publisher
    ..P-mTOR was most highly expressed in FTC but was also increased in HCC, suggesting that drugs targeting this pathway may be useful for treatment of tumors unresponsive to conventional therapies. ..
  4. Mandal R, Hardin H, Baus R, Rehrauer W, Lloyd R. Analysis of miR-96 and miR-133a Expression in Gastrointestinal Neuroendocrine Neoplasms. Endocr Pathol. 2017;28:345-350 pubmed publisher
    ..The study suggests that analysis of these two microRNAs by qRT-PCR may be useful in detecting more aggressive GI-NENs and that ISH analysis may also assist in the evaluation of patients with GI-NENs. ..
  5. Hardin H, Guo Z, Shan W, Montemayor Garcia C, Asioli S, Yu X, et al. The roles of the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progression. Am J Pathol. 2014;184:2342-54 pubmed publisher
  6. Xu J, Hardin H, Zhang R, Sundling K, Buehler D, Lloyd R. Stage-Specific Embryonic Antigen-1 (SSEA-1) Expression in Thyroid Tissues. Endocr Pathol. 2016;27:271-275 pubmed
    ..SSEA-1 is a marker that detects malignant thyroid neoplasms in formalin-fixed paraffin-embedded thyroid tissue sections and may be a useful marker for thyroid cancer stem-like cells. ..
  7. Chu Y, Hardin H, Schneider D, Chen H, Lloyd R. MicroRNA-21 and long non-coding RNA MALAT1 are overexpressed markers in medullary thyroid carcinoma. Exp Mol Pathol. 2017;103:229-236 pubmed publisher
    ..This study examines the expression of microRNA-21 (miR-21) and lncRNA MALAT1 in medullary thyroid carcinomas (MTCs) and their effects on tumor behavior...
  8. Matson D, Hardin H, Buehler D, Lloyd R. AKT activity is elevated in aggressive thyroid neoplasms where it promotes proliferation and invasion. Exp Mol Pathol. 2017;: pubmed publisher
    ..A reduction in invasion was also observed in the cancer stem cell compartment. Targeting AKT activity in the clinical setting may slow the growth and spread of aggressive thyroid neoplasms, and target the tumor stem cell compartment...